CTLA4 and cancer: Immune checkpoint blockade has the broadest impact in different types of cancer immunotherapy, with some antibodies against the cytotoxic T lymphocyte antigen 4 (CTLA4) or programmed cell death 1 (PD1)—PD1 ligand 1 (PD-L1) axis being approved for many different cancers.